Company intelligence / Profile preview
SignaBlok, Inc.
Shrewsbury, Massachusetts, United Statessignablok.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SignaBlok’s lead program is a macrophage-restricted TREM‑1 inhibitor peptide therapy. In preclinical models of pancreatic cancer, this drug prevented recurrence, improved complete response rate and survival when administered after standard chemotherapy, reversed immunosuppression, overcame resistance to anti-PD-L1 immunotherapy, and was shown to be safe and well-tolerated in rodents. The SCHOOL technology platform underpins these programs with a novel mechanism of action.
- Therapeutic areas
- OncologyImmunologyCardiovascularInfectious Diseases
- Modalities
- Peptides (SCHOOL peptides)Nanoparticles/nanosystemsSmall moleculesRNAs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on SignaBlok, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SignaBlok, Inc..